Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma.

Published on Jul 1, 2021in Clinical and Translational Radiation Oncology
· DOI :10.1016/J.CTRO.2021.06.008
Rutvij A. Khanolkar (U of C: University of Calgary), Harvey Quon13
Estimated H-index: 13
(U of C: University of Calgary)
+ 6 AuthorsKevin Martell5
Estimated H-index: 5
(U of C: University of Calgary)
Source
Abstract
Abstract null null Purpose null It has previously been shown that increased wait times for prostatectomy are associated with poorer outcomes in intermediate-risk prostatic carcinoma (PCa). However, the impact of wait times on PCa outcomes following low-dose-rate brachytherapy (LDR-BT) are unknown. null null null Methods and Materials null We retrospectively reviewed 466 intermediate-risk PCa patients that underwent LDR-BT at a single comprehensive cancer center between 2003 and 2016. Wait times were defined as the time from biopsy to LDR-BT. The association of wait times with outcomes was evaluated using Cox and Fine-Gray regression in both univariate and multivariate models. null null null Results null Median (interquartile range) follow-up and wait time for all patients were 8.1 (6.3–10.4) years and 5.1 (3.9–6.9) months, respectively. Among NCCN unfavourable intermediate-risk (UIR) patients (n = 170; 36%), increased wait times predicted both a greater cumulative incidence of recurrence [MHR = 1.01/month of wait time (95% CI: 1.00–1.03); P = 0.044] and metastases [MHR = 1.04/month of wait time (95% CI: 1.02–1.06); P  null null null Conclusions null Resource constraints within this center’s public healthcare system have contributed to waitlists exceeding 5-months in length. This study finds that patients with UIR PCa experience a 1% increase in the risk of recurrence and 4% increase in the risk of metastases with each additional month of delay in definitive disease management. Preventing such extended management delays in LDR-BT may improve disease-related outcomes in patients with PCa.
📖 Papers frequently viewed together
2019
7 Authors (Michel D. Wissing, ..., Liron Kogan)
20203.40Hpb
1 Citations
References25
Newest
#1Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
#2MaryBeth B. Culp (ACS: American Cancer Society)H-Index: 3
Last. Stacey A. Fedewa (ACS: American Cancer Society)H-Index: 43
view all 5 authors...
BACKGROUND: Previous studies reported that prostate cancer incidence rates in the United States (US) declined for local-stage disease and increased for regional- and distant-stage disease following the US Preventive Services Task Force recommendations against prostate-specific antigen-based screening for men aged ≥75 in 2008 and for all men in 2012. It is unknown, however, whether these patterns persisted through 2016. METHODS: Based on the US Cancer Statistics Public Use Research Database, we e...
28 CitationsSource
#1Ahmed S. Zakaria (UdeM: Université de Montréal)H-Index: 7
#2Félix Couture (Université de Sherbrooke)H-Index: 3
Last. Kevin C. Zorn (UdeM: Université de Montréal)H-Index: 34
view all 10 authors...
PURPOSE Most Canadian hospitals face significant reductions in operating room access during the summer. We sought to assess the impact of longer wait times on the oncological outcomes of localized prostate cancer patients following robotic-assisted radical prostatectomy (RARP). METHODS We conducted a retrospective review of a prospectively maintained RARP database in two high-volume academic centers, between 2010 and 2019. Assessed outcomes included the difference between post-biopsy UCSF-CAPRA ...
5 CitationsSource
#1Camille Maringe (Lond: University of London)H-Index: 18
#2James Spicer ('KCL': King's College London)H-Index: 52
Last. Ajay Aggarwal (Lond: University of London)H-Index: 18
view all 8 authors...
Summary Background Since a national lockdown was introduced across the UK in March, 2020, in response to the COVID-19 pandemic, cancer screening has been suspended, routine diagnostic work deferred, and only urgent symptomatic cases prioritised for diagnostic intervention. In this study, we estimated the impact of delays in diagnosis on cancer survival outcomes in four major tumour types. Methods In this national population-based modelling study, we used linked English National Health Service (N...
369 CitationsSource
#1Jack W. London (Thomas Jefferson University)H-Index: 9
Last. Christopher McNair (Thomas Jefferson University)H-Index: 13
view all 5 authors...
PURPOSEWhile there are studies under way to characterize the direct effects of the COVID-19 pandemic on the care of patients with cancer, there have been few quantitative reports of the impact that...
56 CitationsSource
#1Douglas Brand (ICR: Institute of Cancer Research)H-Index: 5
#2Alison Tree (ICR: Institute of Cancer Research)H-Index: 20
Last. N OommenH-Index: 1
view all 51 authors...
Summary Background Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic body radiotherapy would allow shorter treatment courses but could increase acute toxicity compared with conventionally fractionated or moderately hypofractionated radiotherapy. We report the acute toxicity findings from a randomised trial of standard-of-care conventionally ...
119 CitationsSource
#1Anders Widmark (Umeå University)H-Index: 48
#2Adalsteinn Gunnlaugsson (Lund University)H-Index: 13
Last. Per Nilsson (Lund University)H-Index: 33
view all 20 authors...
Summary Background Hypofractionated radiotherapy for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies comparing moderately hypofractionated and conventionally fractionated radiotherapy support the clinical use of moderate hypofractionation. To date, there are no published randomised studies on ultra-hypofractionated radiotherapy. Here, we report the outcomes of the Scandinavian HYPO-RT-PC phase 3 trial with the ai...
198 CitationsSource
#1William C. Jackson (UM: University of Michigan)H-Index: 16
#2Jessica Silva (UM: University of Michigan)H-Index: 1
Last. Daniel E. Spratt (UM: University of Michigan)H-Index: 50
view all 21 authors...
Purpose Utilization of stereotactic body radiation therapy (SBRT) for treatment of localized prostate cancer is increasing. Guidelines and payers variably support the use of prostate SBRT. We therefore sought to systematically analyze biochemical recurrence-free survival (bRFS), physician-reported toxicity, and patient-reported outcomes after prostate SBRT. Methods and Materials A systematic search leveraging Medline via PubMed and EMBASE for original articles published between January 1990 and ...
93 CitationsSource
#1Mary E. Westerman (Mayo Clinic)H-Index: 12
#2Vidit Sharma (Mayo Clinic)H-Index: 15
Last. Robert Jeffrey Karnes (Mayo Clinic)H-Index: 21
view all 9 authors...
INTRODUCTION: To determine the impact of time from biopsy to surgery on outcomes following radical prostatectomy (RP) as the optimal interval between prostate biopsy and RP is unknown. MATERIAL AND METHODS: We identified 7, 350 men who underwent RP at our institution between 1994 and 2012 and had a prostate biopsy within one year of surgery. Patients were grouped into five time intervals for analysis: ≤ 3 weeks, 4-6 weeks, 7-12 weeks, 12-26 weeks, and > 26 weeks. Oncologic outcomes were stratifi...
9 CitationsSource
#1Laurence Klotz (U of T: University of Toronto)H-Index: 85
Purpose of Review Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad consensus that men with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 disease, PSA >10, younger men and African-Americans are often excluded.
19 CitationsSource
#1Michael Peacock (TBCC: Tom Baker Cancer Centre)H-Index: 3
#1Michael Peacock (TBCC: Tom Baker Cancer Centre)H-Index: 3
Last. Siraj Husain (TBCC: Tom Baker Cancer Centre)H-Index: 7
view all 8 authors...
Abstract Purpose The aim of this study is to report the long-term outcomes and toxicities from a large cohort of patients with localized prostate cancer treated with low-dose-rate intraoperatively planned brachytherapy. Methods and Materials Prostate-specific antigen levels, urinary symptoms, and erectile function were recorded at baseline, and each followup visit was then entered into a prospective database. Urinary toxicity requiring procedural intervention was retrospectively verified using a...
8 CitationsSource
Cited By0
Newest